Another effective strategy is combining PI3K-AKT pathway inhibitors with other treatments that are more selective for tumor cells, such as targeted therapies against tumor-specific antigens or immunotherapies (Fresno et al., 2004; Alzahrani, 2019; Fattahi et al., 2020; Yu et al., 2022). The gene discussed is PIK3CB; the disease is neoplasm.